Meds Apotek AB

Meds Apotek AB maintains a strong liquidity position, with a current ratio of 1.63, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score is high, supported by a cash and equivalents balance of 45.17 million SEK, which provides a buffer against short-term obligations. However, the company reported negative operating cash flow of -21.23 million SEK, which may signal operational inefficiencies or increased working capital requirements. Profitability metrics for Meds Apotek AB show a return on equity (ROE) of 6.02% and a return on assets (ROA) of 2.85%. These figures are below the industry median for ROE and ROA, suggesting the company is underperforming in terms of capital efficiency and asset utilization. The company's operating income was negative at -2.41 million SEK, indicating a decline in profitability compared to gross profit of 56.39 million SEK. Geographically and segment-wise, Meds Apotek AB's revenue is concentrated in its domestic market, with no disclosed international operations or segment breakdowns in the latest financials. This lack of diversification may expose the company to regional economic fluctuations and regulatory changes, increasing its concentration risk. The company's growth trajectory appears mixed. While it reported a net income of 7.73 million SEK, the negative operating income and operating cash flow suggest operational challenges. Analysts have provided a mean price target of 52.50 SEK, with a median of 52.50 SEK, and a mean recommendation of 1.50, indicating a generally positive outlook. However, the absence of a clear revenue growth rate or segment-specific growth projections limits the visibility of future performance. Risk factors for Meds Apotek AB include a low liquidity risk and a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.05, indicating a conservative capital structure with minimal leverage. However, the negative operating cash flow and the absence of disclosed capital expenditure plans may signal potential liquidity constraints in the future. Recent events and filings for Meds Apotek AB do not show any material changes or significant corporate actions in the latest available data. The company's free cash flow of 20.30 million SEK suggests it has the capacity to fund operations and potentially return value to shareholders. However, the capital expenditure of -7.61 million SEK indicates ongoing investment in infrastructure or expansion, which may impact short-term liquidity.